Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2020

Open Access 01-12-2020 | Myocardial Infarction | Research article

Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction

Authors: Damien Legallois, Clémence Macquaire, Amir Hodzic, Stéphane Allouche, Ismaïl El Khouakhi, Alain Manrique, Paul Milliez, Eric Saloux, Farzin Beygui

Published in: BMC Cardiovascular Disorders | Issue 1/2020

Login to get access

Abstract

Background

Left ventricular remodeling following ST-elevation myocardial infarction (STEMI) is associated with poor outcome, including heart failure (HF). Neprilysin inhibition leads to improved outcome in patients with altered left ventricular ejection fraction (LVEF).

Methods

We aimed to assess the association between serum levels of neprilysin and left ventricular (LV) volumes, function and remodeling in STEMI patients with successful myocardial reperfusion and no clinical sign of HF. Sixty-eight patients were admitted for STEMI and had both plasma neprilysin measurement at baseline and 3D transthoracic echocardiogram at baseline and after a median follow-up of 7 months. We compared 3 groups: a group with a low-level of plasma neprilysin (< 125 pg/mL, i.e. the lower limit of detection of the assay) and the two other groups were defined as being below or above the median value of the remaining samples.

Results

Median age was 58.5 ± 12.8 years and 56 (82.4%) were men. Median LVEF was 45.0 ± 8.5%. Baseline characteristics were comparable between groups (low-level of neprilysin group [≤125 pg/mL, n = 38], medium-level of neprilysin group [126–450 pg/mL, n = 15] and a high-level group [> 450 pg/mL, n = 15]). At baseline there was a non-significant trend towards lower end-diastolic volume (p = 0.07) but significantly lower LVEF in the high neprilysin group (46.4 ± 8.3%, 47.1 ± 8.1% and 39.1 ± 6.9%, p < 0.01). At follow-up, the magnitude of LVEF increase was significantly more important in the high neprilysin group compared to the other groups (p = 0.022 for relative change in LVEF and 6.6 ± 7.3%, 3.6 ± 9.0% and 11.3 ± 8.4%, p = 0.031 for absolute change in LVEF) resulting in similar LVEF levels at follow-up between all groups (53.0 ± 8.9%, 50.6 ± 9.7% and 50.4 ± 9.9%, p = 0.55).

Conclusions

Initial high neprilysin levels may identify patients with stunned myocardium early after STEMI, with a recovery of contractility leading to improved LVEF at follow-up. Future studies will have to assess the role of neprilysin in the setting of STEMI and the potential benefit of its blockade.
Literature
1.
go back to reference Huttin O, Coiro S, Selton-Suty C, Juillière Y, Donal E, Magne J, Sadoul N, Zannad F, Rossignol P, Girerd N. Prediction of left ventricular remodeling after a myocardial infarction: role of myocardial deformation: a systematic review and meta-analysis. PLoS One. 2016;11:e0168349.CrossRef Huttin O, Coiro S, Selton-Suty C, Juillière Y, Donal E, Magne J, Sadoul N, Zannad F, Rossignol P, Girerd N. Prediction of left ventricular remodeling after a myocardial infarction: role of myocardial deformation: a systematic review and meta-analysis. PLoS One. 2016;11:e0168349.CrossRef
2.
go back to reference Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.CrossRef Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165.CrossRef
3.
go back to reference St John Sutton M, Lee D, Rouleau JL, Goldman S, Plappert T, Braunwald E, Pfeffer MA. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107:2577–82.CrossRef St John Sutton M, Lee D, Rouleau JL, Goldman S, Plappert T, Braunwald E, Pfeffer MA. Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation. 2003;107:2577–82.CrossRef
4.
go back to reference Dorn GW 2nd. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol. 2009;6:283–91.CrossRef Dorn GW 2nd. Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol. 2009;6:283–91.CrossRef
5.
go back to reference Palardy M, Ducharme A, O'Meara E. Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI. Curr Heart Fail Rep. 2007;4:190–7.CrossRef Palardy M, Ducharme A, O'Meara E. Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI. Curr Heart Fail Rep. 2007;4:190–7.CrossRef
6.
go back to reference Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998;97:2202–2212. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998;97:2202–2212.
7.
go back to reference Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005;111:3411–9.CrossRef Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005;111:3411–9.CrossRef
8.
go back to reference Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.CrossRef Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.CrossRef
9.
go back to reference Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44:913–8.CrossRef Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44:913–8.CrossRef
10.
go back to reference Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum H, Webb DJ, Cockcroft JR. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol. 2001;52:159–64.CrossRef Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum H, Webb DJ, Cockcroft JR. Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol. 2001;52:159–64.CrossRef
11.
go back to reference Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401–14.CrossRef Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401–14.CrossRef
12.
go back to reference McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.CrossRef McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.CrossRef
13.
go back to reference Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018;36:e12435.CrossRef Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018;36:e12435.CrossRef
14.
go back to reference Bernelin H, Mewton N, Si-Mohamed S, Croisille P, Rioufol G, Bonnefoy-Cudraz E, Douek P, Dufay N, Amaz C, Jossan C, Ovize M, Bochaton T. Neprilysin levels at the acute phase of ST-elevation myocardial infarction. Clin Cardiol. 2019;42:32–8.CrossRef Bernelin H, Mewton N, Si-Mohamed S, Croisille P, Rioufol G, Bonnefoy-Cudraz E, Douek P, Dufay N, Amaz C, Jossan C, Ovize M, Bochaton T. Neprilysin levels at the acute phase of ST-elevation myocardial infarction. Clin Cardiol. 2019;42:32–8.CrossRef
15.
go back to reference Reddy YNV, Iyer SR, Scott CG, Rodeheffer RJ, Bailey K, Jenkins G, Batzler A, Redfield MM, Burnett JC Jr, Pereira NL. Soluble neprilysin in the general population: clinical determinants and its relationship to cardiovascular disease. J Am Heart Assoc. 2019;8:e012943.PubMedPubMedCentral Reddy YNV, Iyer SR, Scott CG, Rodeheffer RJ, Bailey K, Jenkins G, Batzler A, Redfield MM, Burnett JC Jr, Pereira NL. Soluble neprilysin in the general population: clinical determinants and its relationship to cardiovascular disease. J Am Heart Assoc. 2019;8:e012943.PubMedPubMedCentral
16.
go back to reference Bacmeister L, Schwarzl M, Warnke S, Stoffers B, Blankenberg S, Westermann D, Lindner D. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol. 2019;114:19.CrossRef Bacmeister L, Schwarzl M, Warnke S, Stoffers B, Blankenberg S, Westermann D, Lindner D. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol. 2019;114:19.CrossRef
17.
go back to reference Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther. 2013;94:445–8.CrossRef Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther. 2013;94:445–8.CrossRef
18.
go back to reference Bayés-Genís A, Barallat J, Galán A, de Antonio M, Domingo M, Zamora E, Urrutia A, Lupón J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65:657–65.CrossRef Bayés-Genís A, Barallat J, Galán A, de Antonio M, Domingo M, Zamora E, Urrutia A, Lupón J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65:657–65.CrossRef
19.
go back to reference Bayés-Genís A, Barallat J, Pascual-Figal D, Nuñez J, Miñana G, Sánchez-Mas J, Galan A, Sanchis J, Zamora E, Pérez-Martínez MT, Lupón J. Prognostic value and kinetics of soluble neprilysin in acute heart failure. JACC Heart Fail. 2015;3:641–4.CrossRef Bayés-Genís A, Barallat J, Pascual-Figal D, Nuñez J, Miñana G, Sánchez-Mas J, Galan A, Sanchis J, Zamora E, Pérez-Martínez MT, Lupón J. Prognostic value and kinetics of soluble neprilysin in acute heart failure. JACC Heart Fail. 2015;3:641–4.CrossRef
20.
go back to reference Núñez J, Núñez E, Barallat J, Bodí V, Miñana G, Pastor MC, Sanchis J, Lupón J, Bayes-Genis A. Serum neprilysin and recurrent admissions in patients with heart failure. J Am Heart Assoc. 2017;6:e005712.CrossRef Núñez J, Núñez E, Barallat J, Bodí V, Miñana G, Pastor MC, Sanchis J, Lupón J, Bayes-Genis A. Serum neprilysin and recurrent admissions in patients with heart failure. J Am Heart Assoc. 2017;6:e005712.CrossRef
21.
go back to reference Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, Schoene N, Schuler G. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000;342:454–60.CrossRef Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, Schoene N, Schuler G. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000;342:454–60.CrossRef
22.
go back to reference Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;191:341–66.CrossRef Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;191:341–66.CrossRef
23.
go back to reference Lippi G, Sanchis-Gomar F. Monitoring b-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge? Int J Cardiol. 2016;219:111–4.CrossRef Lippi G, Sanchis-Gomar F. Monitoring b-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge? Int J Cardiol. 2016;219:111–4.CrossRef
24.
go back to reference Hole T, Hall C, Skaerpe T. N-terminal proatrial natriuretic peptide predicts two-year remodelling in patients with acute transmural myocardial infarction. Eur Heart J. 2004;25:416–23.CrossRef Hole T, Hall C, Skaerpe T. N-terminal proatrial natriuretic peptide predicts two-year remodelling in patients with acute transmural myocardial infarction. Eur Heart J. 2004;25:416–23.CrossRef
25.
go back to reference Manhenke C, Ueland T, Jugdutt BI, Godang K, Aukrust P, Dickstein K, Ørn S. The relationship between markers of extracellular cardiac matrix turnover: infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. Eur Heart J. 2014;35:395–402.CrossRef Manhenke C, Ueland T, Jugdutt BI, Godang K, Aukrust P, Dickstein K, Ørn S. The relationship between markers of extracellular cardiac matrix turnover: infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. Eur Heart J. 2014;35:395–402.CrossRef
26.
go back to reference Urbano-Moral JA, Lopez-Haldon JE, Fernandez M, Mancha F, Sanchez A, Rodriguez-Puras MJ, Villa M, Lopez-Pardo F, Diaz de la Llera L, Valle JI, Martinez A. Prognostic value of different serum biomarkers for left ventricular remodelling after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart. 2012;98:1153–9.CrossRef Urbano-Moral JA, Lopez-Haldon JE, Fernandez M, Mancha F, Sanchez A, Rodriguez-Puras MJ, Villa M, Lopez-Pardo F, Diaz de la Llera L, Valle JI, Martinez A. Prognostic value of different serum biomarkers for left ventricular remodelling after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart. 2012;98:1153–9.CrossRef
27.
go back to reference Vodovar N, Séronde MF, Laribi S, Gayat E, Lassus J, Januzzi JL Jr, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D, Cohen-Solal A, Richards AM, Launay JM, Mebazaa A, Network GREAT. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating Neprilysin activity in heart failure. JACC Heart Fail. 2015;3:629–36.CrossRef Vodovar N, Séronde MF, Laribi S, Gayat E, Lassus J, Januzzi JL Jr, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D, Cohen-Solal A, Richards AM, Launay JM, Mebazaa A, Network GREAT. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating Neprilysin activity in heart failure. JACC Heart Fail. 2015;3:629–36.CrossRef
Metadata
Title
Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction
Authors
Damien Legallois
Clémence Macquaire
Amir Hodzic
Stéphane Allouche
Ismaïl El Khouakhi
Alain Manrique
Paul Milliez
Eric Saloux
Farzin Beygui
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2020
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-020-01578-y

Other articles of this Issue 1/2020

BMC Cardiovascular Disorders 1/2020 Go to the issue